NCT07017270 Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
| NCT ID | NCT07017270 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Unity Health Toronto |
| Condition | Kidney Disease, Chronic |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-11-27 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 100 participants in total. It began in 2025-11-27 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 2. Receiving chronic maintenance hemodialysis or peritoneal dialysis for ≥ 90 days 3. confirmed DM2 based on medical history and current or prior receipt of an oral hypoglycemic agent and/or insulin. 4. Ability to provided informed consent or through their substitute decision maker Exclusion Criteria: 1. Type 1 DM 2. Use of a GLP-1-RA within 30 days prior to screening 3. Personal or first-degree relative(s) with a history of type 2 multiple endocrine neoplasia syndrome or medullary thyroid cancer, or acute pancreatitis (within 180 days of study screening) 4. Confirmed pregnancy, women of childbearing potential 5. Known hypersensitivity to GLP-1-RA 6. Expected to recover kidney function, stop hemodialysis, pursue palliative care, or transplantation within 6 months 7. Enrolment in another clinical trial judged by the investigator to interact with the effect of GLP1-RA
Contact & Investigator
Dr. Ron Wald, MD
PRINCIPAL INVESTIGATOR
Unity Health Toronto
Frequently Asked Questions
Who can join the NCT07017270 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Kidney Disease, Chronic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07017270 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07017270 currently recruiting?
Yes, NCT07017270 is actively recruiting participants. Contact the research team at ron.wald@unityhealth.to for enrollment information.
Where is the NCT07017270 trial being conducted?
This trial is being conducted at Toronto, Canada, Toronto, Canada.
Who is sponsoring the NCT07017270 clinical trial?
NCT07017270 is sponsored by Unity Health Toronto. The principal investigator is Dr. Ron Wald, MD at Unity Health Toronto. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.